Latest news with #OlliHuotariEVP
Yahoo
02-05-2025
- Business
- Yahoo
301,521 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 301,521 A shares have been converted into 301,521 B shares. The conversion has been entered into the Trade Register on 2 May 2025. The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 32,450,742 A shares and 108,683,536 B shares. The number of votes of the company's shares is after the conversion 757,698,376. Orion Corporation René LindellCFO Olli HuotariEVP, Corporate Functions Contact person:Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in to access your portfolio
Yahoo
11-03-2025
- Business
- Yahoo
Orion Group Financial Statement documents 2024 and Remuneration Report published
ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT11 MARCH 2025 at 11.15 EET Orion Group Financial Statement documents 2024 and Remuneration Report published Orion Group's Financial Statement documents for 2024 have been published. The documents are available in Finnish and English on the Company's website at and are attached to this release. Financial Statement documents include the company's Financial Statements, the Report by the Board of Directors, the Sustainability Statement (as part of the Report by the Board of Directors), and the Corporate Governance Statement (as part of the Report by the Board of Directors). The Financial Statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements as xHTML file. The primary statements and notes to the Consolidated financial statements have been labelled with XBRL tags. Authorised Public Accountants KPMG Oy Ab has provided an independent auditor's reasonable assurance report on Orion's ESEF Financial Statements in accordance with ISAE 3000 (revised). Orion's Sustainability Statement is prepared according to the European Sustainability Reporting Standards (ESRS) and the Finnish Accounting Act's Chapter 7 on sustainability reporting. Authorised Sustainability Audit Firm KPMG Oy Ab has assured the report at a limited assurance level in accordance with ISAE 3000 (revised). The official Financial Statement documents in accordance with the requirements of the Finnish Accounting Act and the Companies Act, which include the Financial Statements, the Report by the Board of Directors, the Sustainability Statement (as part of the Report by the Board of Directors), the Corporate Governance Statement (as part of the Report by the Board of Directors), the Auditor's Report, and the Assurance Report on the Sustainability Report are available in Finnish at Orion's Remuneration Report 2024 adopted by the Board of Directors has been published as a separate report in Finnish and English on the Company's website at and is attached to this release. Orion Corporation Liisa HurmePresident and CEO Olli HuotariEVP, Corporate Functions Contact person:Tuukka Hirvonen, Investor Relationstel. +358 10 426 2721 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. Attachments 74370029VAHCXDR7B745-2024-12-31-0-en Remuneration report 2024 Orion Financial Statement Documents 2024
